首页> 外文期刊>International journal of hyperthermia: The official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group >Therapeutical effect of intrapleural perfusion with hyperthermic chemotherapy on malignant pleural effusion under video-assisted thoracoscopic surgery
【24h】

Therapeutical effect of intrapleural perfusion with hyperthermic chemotherapy on malignant pleural effusion under video-assisted thoracoscopic surgery

机译:视频辅助胸腔镜手术下牙周灌注对高温化疗对恶性胸腔积液的疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Patients with malignant pleural effusions (MPEs) have limited life expectancy. This study aims to investigate the feasibility of intrapleural perfusion with hyperthermic chemotherapy (IPHC) under video-assisted thoracoscopic surgery on MPE patients.Methods: MPE patients were enrolled in the study and treated with IPHC. The treatment response was classified as complete response (CR, no re-accumulation of pleural fluid for 4weeks), partial response (PR, re-accumulation above the post-IPHC level but below the pre-IPHC level for four weeks), no response (NR; re-accumulation or above the pre-IPHC level). The change of Karnofsky performance score (KPS) and tumour markers were also recorded. Follow-up was done every two weeks during first month and monthly thereafter until death.Results: Eighty patients included 46 males and 34 females were included in the study. The total response rate was 100%, with 71.3% of CR and 28.7% of PR. The KPS scores were significantly elevated and the level of tumour markers in pleural effusion were dramatically decreased after IPHC. The median survival was 16.8months ranged from 2.1 to 67.4months. One-year and two-year survival rates were 82.5% and 23.8%, respectively. There were no serious clinical compilations during IPHC treatment.Conclusions: IPHC is a safety, effective and promising approach for MPE patients. It provides well survival benefit and minor toxicities.
机译:背景:恶性胸腔积液(MPE)的患者的预期寿命有限。本研究旨在探讨在MPE患者的视频辅助胸腔镜手术下对高温化疗(IPHC)的腹膜内灌注的可行性。方法:MPE患者注册研究并用IPHC治疗。治疗反应被归类为完全反应(CR,没有重新积聚4周的胸腔液),部分反应(PR,在后Iphc水平以上重新积累但低于IPHC水平4周),没有反应(NR;重新积累或高于IPHC水平)。还记录了Karnofsky性能评分(KPS)和肿瘤标志物的变化。在第一个月和每月之前每两周一次完成随访,直到死亡。结果:八十名患者包括46名男性,在研究中纳入34名女性。总响应率为100%,3.3%的CR和28.7%的PR。 KPS评分明显升高,胸腔积液中肿瘤标志物的水平显着降低。中位生存率为16.8个月,范围为2.1至67.4个月。一年和两年的生存率分别为82.5%和23.8%。 IPHC治疗过程中没有严重的临床编制。结论:IPHC是MPE患者的安全,有效和有希望的方法。它提供了良好的生存益处和轻微的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号